Medikamentös induzierte Psychosen

Zusammenfassung

Es gibt eine Vielzahl von Medikamenten, die unerwünschte psychische Arzneimittelwirkungen (UAW) auslösen können. Diese Medikamente werden häufig in anderen Fachdisziplinen als der Psychiatrie eingesetzt und verordnet. Viele Medikamente können das zentrale Nervensystem beeinflussen und auch psychotische Zustandsbilder verursachen. Häufig werden solche UAWs übersehen, nicht als Medikamenteneffekt identifiziert oder fälschlicherweise als Ausdruck einer eigenständigen psychischen Störung missinterpretiert. Der folgende Artikel gibt eine Übersicht über die wichtigsten Medikamentengruppen, die eine psychotische Symptomatik induzieren können, und Hinweise zur Therapie.

Summary

The number of drugs that can induce psychiatric symptoms as side-effect is large. These drugs are often prescribed and in therapeutic use in other medical disciplines. Many of these drugs have side effects on the central nervous system and can induce psychotic symptoms. Frequently, these side effects are not diagnosed, not identified as drug side-effects or misdiagnosed as psychiatric disorders. The following article presents an overview of the important drugs that can induce psychosis and of the therapy of these psychotic syndromes.

Key words

delirium - drug induced - psychosis

Literatur

• 1 Andrejak M, Schmitt JL, Tondriaux A. Neurologic side effects of fluoroquinolones.  Therapie. 1992;  47 415-418
• 2 Baile WF. Neuropsychiatric disorders in cancer patients.  Curr Opin Oncol. 1996;  8 182-187
• 3 Barry JJ, Franklin K. Amiodarone-induced delirium.  Am J Psychiatry. 1999;  156 119
• 4 Bikadoroff G. Mental changes associated with tocainide, a new antiarrhythmic.  Can J Psychiatry. 1987;  32 219-221
• 5 Bonhoeffer K. Die Psychosen im Gefolge von akuten Infektionen, Allgemeinerkrankungen und inneren Erkrankungen. Leipzig Wien, Deuticke 1912
• 6 Bullinger M. Psychotropic effects of non-psychotropic drugs. Adv Drug React Acute Poisoning Rev 1987: 141-167
• 7 Bush DF, Liss CL, Morton A. An open multicentre long-term treatment evaluation of sinemet.  Neurology. 1989;  39 101-104
• 8 Campbell HM, Schubert DSP. Delirium after cessation of glucocorticoid therapy.  Gen Hosp Psychiatry. 1991;  13 270-272
• 9 Clarke CWF, El-Mahdi EO. Confusion and paranoia associated with oral tocianide.  Postgrad Med. 1985;  61 79-81
• 10 Cummings JL. Behavioural complications of drug treatment in Parkinson's disease.  J Am Geriatr Soc. 1991;  39 708-716
• 11 Deleu D, Schmedding E. Acute psychosis as idiosyncratic reaction to quinidine: report of two cases.  BMJ. 1987;  294 1001-1002
• 12 Downham TF, Cawley RA, Salley SO. Systemic toxic reactions to procaine penicillin.  Sex Transm Dis. 1978;  5 4-9
• 13 Duroziez P. De deliere et du coma digitaliques.  Gaz Hebedo Med Chir. 1874;  11 780-785
• 14 Eisendrath SJ, Sweeny MA. Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations.  Am J Psychiatry. 1987;  144 506-507
• 15 Farrington J, Stoudemire A, Tierney J. The role of ciprofloxacin in a patient with delirium due to multiple etiologies.  Gen Hosp Psychiatry. 1995;  17 47-53
• 16 Fisher BW, Flowerdew G. A simple model for predicting postoperative delirium in older patients undergoing elective orthopedic surgery.  J Amer Geriat Psychiat. 1995;  43 175-178
• 17 Fischer P, Assem-Hilger E. Delir/Verwirrtheitszustand. In: Förstl H (Hrsg.) Lehrbuch der Gerontopsychiatrie und -psychotherapie. Grundlagen - Klinik - Therapie. Stuttgart New York: Georg Thieme Verlag 2003: 394-408
• 18 Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly.  JAMA. 1990;  263 1097-1101
• 19 Galanakis P, Bickel H, Gradinger R. Acute confusional state in the elderly following hip surgery: incidence, risk factors and complications.  J Geriat Psychiatry. 2001;  16 349-355
• 20 George J, Bleasdale S, Singleton SJ. Causes and prognosis of delirium in elderly patients admitted to a district general hospital.  Age Ageing. 1997;  26 423-427
• 21 Goepfert C. Häufig unerkannt: medikamentös induzierte Psychosen.  NeuroTransmitter. 2005;  16 66-71
• 22 Gray SL, Katie VL, Larson EB. Drug-induced cognition disorders in the elderly.  Drug Safety. 1999;  21 101-122
• 23 Greenblatt DJ, Shader RI. Digitalis toxicity. In: Shader RI (ed.) Psychiatric complications of medical drugs. New York, Raven Press 1972: 25-47
• 24 Hollweg M, Kapfhammer HP, Krupinski M, Möller HJ. Psychopathologische Syndrome unter Behandlung mit Gyrasehemmern.  Nervenarzt. 1997;  68 38-47
• 25 Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predicitve model and interrelationship with baseline vulnerability.  JAMA. 1996;  275 852-858
• 26 Joseph CL, Siple C, McWhorter K. Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports.  J Am Geriatr Soc. 1995;  43 47-50
• 27 Johnson AG, Day RO, Seldon WA. A functional psychosis precipitated by quinidine.  Med J Aust. 1990;  153 47-49
• 28 Jungst G, Mohr R. Side effects of ofloxacin in clinical trials and in postmarketing surveillance.  Drugs. 1987;  1 144-149
• 29 Keller H. Comparison of adverse drug effect profile of different substances such as penecillins, teracyclines, sulfonamides and quinolones.  Infection. 1991;  19 19-24
• 30 Keller S, Frishman WH. Neuropsychiatric effects of cardiovascular drug therapy.  Cardiol Rev. 2003;  11 73-93
• 31 Kurlan R, Miller C, Levy R. Long term experience with pergolide treatment of advanced parkinsonism.  Neurology. 1985;  35 738-742
• 32 Lautenschlager NT, Förstl H. Organic psychosis: insight into the biology of psychosis.  Curr Psych Rev. 2001;  3 319-325
• 33 Levkoff S, Cleary P, Liptzin B. Epidemiology of delirium: an overbiew of research issues and findings.  International Psychogeriatrics. 1991;  3 149-167
• 34 Lieberman AN, Goldstein M, Gopinathan G. Further studies with pergolide in Parkinsons disease.  Neurology. 1982;  32 1182-1184
• 35 Lieberman AN, Goldstein M, Gopinathan G. D-1 and D-2 agonists in Parkinsons disease.  Can J Neurol Sci. 1987;  14 466-473
• 36 Lupien S, Lecours AR, Lussier I. Basal cortisol levels and cognitive decline in human aging.  J Neurosci. 1994;  14 2893-2903
• 37 Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer.  J Affect Disord. 1998;  50 245-251
• 38 Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly.  Drugs & Aging. 1999;  15 15-28
• 39 Morrison RL, Katz IR. Drug related cognitive impairment: current progress and recurrent problems.  Annu Rev Gerontol Geriatr. 1989;  9 232-279
• 40 Mueller TH, Beeber AR. Delirium from valproic acid with lamotrigine.  Am J Psychiatry. 2004;  161 1128-1129
• 41 Mula M, Trimble MR, Lhatoo SD, Sander JWAS. Topiramate and psychiatric adverse events in patients with epilepsy.  Epilepsia. 2003;  44 659-663
• 42 Mulhall JP, Bergmann LS. Cirpofloxacin-induced acute psychosis.  Urology. 1995;  46 102-103
• 43 Nicholls PJN. Neurotoxicity of penicillin.  J Antimikrob Chemother. 1980;  6 161-165
• 44 O'Keeffe ST, Devlin JG. Delirium and the dexamethasone suppression test in the elderly.  Neuropsychobiology. 1994;  30 153-156
• 45 O'Keeffe ST, Lavan SN. The clinical significance of delirium subtypes.  Age Ageing. 1999;  28 115-119
• 46 Patten SB, Love EJ. Neuropsychiatric adverse reactions: passive reports to Health and Welfare Canada's Adverse Drug Reaction Database (1965 - present).  Int J Psychiatry Med. 1994;  24 45-62
• 47 Patten SB, Neutel I. Corticosteroid-induced adverse psychiatric effects.  Drug Safety. 2000;  22 111-122
• 48 Perantie DC, Brown ES. Corticosteroids, Immune Suppression, and Psychosis.  Current Psychiatric Reports. 2002;  4 171-176
• 49 Rice H, Haltzman S, Tucek C. Mania associated with procainamid.  Am J Psychiatry. 1988;  145 129-130
• 50 Sarvay SM, Marke J, Steinberg MD. „Doom anxiety” and delirium in lidocaine toxicity.  Am J Psychiatry. 1987;  144 159-163
• 51 Schaefer M, Engelbrecht MA, Gut O, Fiebich BI, Bauer J, Schmidt F, Grunze H, Lieb K. Interferon alpha (IFN a) and psychiatric syndromes. A review.  Prog Neur Psychopharm Biol Psychiatry. 2002;  26 731-746
• 52 Schah PM, Mulert R. Safety profile of quinolones.  Eur Urol. 1990;  17 46-51
• 53 Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis.  J Antimicrob Chemother. 1991;  27 405-425
• 54 Sirois F. Steroid psychosis: a review.  Gen Hosp Psychiatry. 2003;  25 27-33
• 55 Slaker RA, Danielson B. Neurotoxicity associated with ceftazidirne therapy in geriatric patients with renal dysfunction.  Pharmacotherapy. 1991;  4 351-352
• 56 Smith DB. Cognitive effects of antiepileptic drugs. In: Smith D, Treiman D, Trimble MR (eds) Neurobehavioral problems in epilepsy. New York: Raven Press 1991: 197-212
• 57 Smith H, Janz TG, Erker M. Digoxin toxicity presenting as altered mental status in a patient with severe chronic obstructive lung disease.  Heart Lung. 1992;  21 78-80
• 58 Smith HL. Cerebral manifestations of digitalis intoxication.  Mayo Clin Proc. 1938;  13 574-575
• 59 Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents.  Ann Intern Med. 1984;  101 92-104
• 60 Sternbach H, State R. Antibiotics: neuropsychiatric effects and psychotropic interactions.  Harv Rev Psychiatry. 1997;  5 214-226
• 61 Stoudemire A, Anfinson T, Edward J. Corticosteroid-induced delirium, and dependency.  Gen Hosp Psychiatry. 1996;  18 196-202
• 62 Tack KJ, Smith JA. The safety profile of ofloxacin.  Am J Med. 1989;  87 78S-81S
• 63 The Medical Letter I. Drugs that cause psychiatric symptoms. Med Lett Drugs Ther 35: 65-70
• 64 Thomas RJ, Reagan DR. Association of a Tourette-like syndrome with ofloxazin.  Ann Pharmacother. 1996;  30 138-141
• 65 Trohman RG, Castellanos D, Castellanos A. Amiodarone-induced delirium.  Ann Intern Med. 1988;  108 68-69
• 66 Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs.  Cancer Treat Rev. 1994;  20 191-214
• 67 Weinrich S, Sarna L. Delirium in the older person with cancer.  Cancer. 1994;  74 2079-2091
• 68 Young BK, Camicioli R, Ganzini L. Neuropsychiatric adverse effects of antiparkinsonian drugs: characteristics, evaluation and treatment.  Drugs Aging. 1997;  10 367-383

Korrespondenzadresse: